MedTrace Logo

Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)

NCT03620357 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2021-03-22

No results posted yet for this study

Summary

A Study to assess if patients with Type 2 diabetes (T2D) who have suboptimal glycemic control using multiple oral agents are able to make lifestyle changes resulting in improved glycemic control by use of real-time continuous glucose monitoring (RT-CGM) and targeted learning modules versus self monitored blood glucose (SMBG) testing.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DEVICE

CGM

CGM Group: Dexcom G6 CGM

DEVICE

SMBG

SMBG Group: Blood Glucose Meter

Sponsors & Collaborators

  • DexCom, Inc.

    lead INDUSTRY

Principal Investigators

  • David Price, MD · DexCom, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-05
Primary Completion
2020-05-27
Completion
2020-11-04
FDA Device
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03620357 on ClinicalTrials.gov